The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

28 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.EBI
Sanford-Burnham Medical Research Institute
Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.EBI
Sanford-Burnham Medical Research Institute
Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.EBI
Sanford-Burnham Medical Research Institute
Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes.EBI
Sanford-Burnham Medical Research Institute
Imidazole-derived agonists for the neurotensin 1 receptor.EBI
Sanford-Burnham Medical Research Institute
Discovery of ML314, a Brain Penetrant Non-Peptidicβ-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.EBI
Sanford-Burnham Medical Research Institute
Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP.EBI
Sanford-Burnham Medical Research Institute
Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.EBI
Sanford-Burnham Medical Research Institute
Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.EBI
Sanford-Burnham Medical Research Institute
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.EBI
Sanford-Burnham Medical Research Institute
Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats.EBI
Sanford-Burnham Medical Research Institute
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.EBI
Sanford-Burnham Medical Research Institute
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.EBI
Sanford-Burnham Medical Research Institute
SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1.EBI
Sanford-Burnham Medical Research Institute
Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP.EBI
Sanford-Burnham Medical Research Institute
Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia.EBI
Sanford-Burnham Medical Research Institute
Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase.EBI
Sanford-Burnham Medical Research Institute
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.EBI
Sanford-Burnham Medical Research Institute
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.EBI
Sanford-Burnham Medical Research Institute
Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules.EBI
Sanford-Burnham Medical Research Institute
Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase.EBI
Sanford-Burnham Medical Research Institute
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.EBI
Sanford-Burnham Medical Research Institute
Therapeutic pyrazolyl thienopyridinesBDB
Fbm Therapeutics
PDE9 inhibitors with imidazo triazinone backboneBDB
H. Lundbeck
Synthesis, Antifolate and Anticancer Activities of N(5) -Substituted 8,10-Dideazatetrahydrofolate Analogues.BDB
Peking University
One-pot synthesis of 4,6-diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38alpha MAP kinase inhibition.BDB
German University In Cairo
7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.BDB
Tokushima Research Institute